My long-term goal on VYNE
アップデート済
Since VYNE Therapeutics has enough cash (148m) for 2021 and even into 2022 (possible to turn profitable in 2021), they have a stable cash burn rate. Indicates their financials are strong.
Break-even reaches 8500 prescriptions a week / 25 million quarter.
Furthermore, with two approved FDA drugs commercialized (AMZEEQ and ZILXI covered by three major PBMS, coverage ahead of schedule ) were AMZEEQ's regular price ($200-$250) will kick in by Q2 and Q3 (due to covid-19). According to today's knowledge, there is no insider selling—instead, insiders buy-in (Perceptive, Blackrock, own BOD, and management team buy).
On-going product pipeline:
FMX114 recently announced a Multi-modal approach, and the intention is to diversify the pipeline. Phase 2 is covered by the budget.
FCD105 was going through Phase 2A. FCD Approval expected End 2023/beginning 2024, and phase 3 will start end of this year. Budget coverage is expected.
Since the reverse split - lowered float from 252 million to 51 million shares outstanding.
VYNE has seven buy ratings with an average target of $20,86, a high target of $40 / a low target of $12.
I am confident we will see a closer trading price near $20 rather than $10 EOY 21.
This is not financial advice.
Break-even reaches 8500 prescriptions a week / 25 million quarter.
Furthermore, with two approved FDA drugs commercialized (AMZEEQ and ZILXI covered by three major PBMS, coverage ahead of schedule ) were AMZEEQ's regular price ($200-$250) will kick in by Q2 and Q3 (due to covid-19). According to today's knowledge, there is no insider selling—instead, insiders buy-in (Perceptive, Blackrock, own BOD, and management team buy).
On-going product pipeline:
FMX114 recently announced a Multi-modal approach, and the intention is to diversify the pipeline. Phase 2 is covered by the budget.
FCD105 was going through Phase 2A. FCD Approval expected End 2023/beginning 2024, and phase 3 will start end of this year. Budget coverage is expected.
Since the reverse split - lowered float from 252 million to 51 million shares outstanding.
VYNE has seven buy ratings with an average target of $20,86, a high target of $40 / a low target of $12.
I am confident we will see a closer trading price near $20 rather than $10 EOY 21.
This is not financial advice.
トレード稼働中
I want to update some key points on VYNE: 8 Oct- SEC 10B5-1 plan submitted for LePore's intention to buy 200k (shares in VYNE's ordinary shares at prevailing interest rates within the next 12 months.)
9th Oct - Piper Sandler announced AMZEEQ total Rx (TRx) up versus prior week 2,439 vs. 2,396. QTD growth rate of 55% in 3Q.
7th Dec - LePore’s first insider’s buy commitment (12,500 at $6.82 PS)
26th Jan - 2 Offerings happened, 1 ended as a market offer, the other at $2.37 ($9.48 PS) for 50m. Cash of 132m in hand the last conference call confirmed.
1st Feb - Perceptive Advisors declares their stake increased (The biggest investor with 18.44% current)
2nd Feb - Blackrock (7.1%) declares their stake increased
12th Feb - Reverse Split (1 for 4) reduced float to 51.33M
1st Mar - Announced new pipeline FMX114
16th Mar - Lepore’s second insider’s buy (12,500 at $7.405), with 25,000 more shares outstanding to go based on his commitment.
Summarized by quiescent
免責事項
これらの情報および投稿は、TradingViewが提供または保証する金融、投資、取引、またはその他の種類のアドバイスや推奨を意図したものではなく、またそのようなものでもありません。詳しくは利用規約をご覧ください。